p53: a potential target antigen for immunotherapy of cancer.
about
Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopesImmunologic aspect of ovarian cancer and p53 as tumor antigen.Vaccines against human carcinomas: strategies to improve antitumor immune responses.CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.Immunity to stemness genes in human cancer.CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination.Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges.Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus AnkaraRecognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMaxStrategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.P53 and expression of immunological markers may identify early stage thyroid tumorsHealthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancerVaccines targeting cancer stem cells: are they within reach?Identification of differentially expressed proteins in spontaneous thymic lymphomas from knockout mice with deletion of p53.Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice.The mutational status of p53 can influence its recognition by human T-cells.
P2860
Q24806913-1B454D1F-D8DD-41C5-B51A-B0180FE577A4Q24814703-E6B73B62-4CE5-4902-B2E7-EBA1D8B3BED0Q33734281-9781D291-A246-41F4-A1A5-8E5BC27FCDF7Q33942390-7DD63BCF-00F1-4DC2-8B3D-7F023A8E9EDDQ33943241-EF01D657-228E-4ABE-9D4C-1B86C29D64B2Q33943864-DAA01A0A-E042-414E-86FE-C96CD2CB9188Q33999909-35CEA3C8-8FF7-48FA-A2F2-9428E8B56217Q34151620-40422982-3137-44E5-804A-A8B5DBE3F733Q34343169-CB8FE673-CE61-4232-A69A-985F5A5A7E3BQ34657661-37A0354D-9D83-48D3-B565-9B0634DE8E4BQ35790603-F436958E-26FF-4103-B4EF-6581BE54DD00Q36430004-F7FE5D89-E891-412A-B044-1C87B330F938Q36469826-55BBF83F-A740-4406-AFA1-1382FED43340Q37220281-C9F04D7D-048B-49A4-8242-99842EA5F4EDQ37288038-2E835BE2-DFDB-47B8-BB78-17C6F3BE4B98Q37939527-4FBEA1A2-465C-4F9A-B21E-9229532B5B85Q41220735-FFCC0F85-C5C8-4DF5-AF2A-2177C3DBB81DQ44960269-F45EAA6C-A975-4E30-B52B-733A91D55240Q50999703-7DF87675-D780-45E5-B6F6-A6F514BE1F63
P2860
p53: a potential target antigen for immunotherapy of cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
p53: a potential target antigen for immunotherapy of cancer.
@ast
p53: a potential target antigen for immunotherapy of cancer.
@en
type
label
p53: a potential target antigen for immunotherapy of cancer.
@ast
p53: a potential target antigen for immunotherapy of cancer.
@en
prefLabel
p53: a potential target antigen for immunotherapy of cancer.
@ast
p53: a potential target antigen for immunotherapy of cancer.
@en
P2093
P1476
p53: a potential target antigen for immunotherapy of cancer.
@en
P2093
Offringa R
Vierboom MP
van der Burg SH
P304
223-33; discussion 233-6
P407
P577
2000-06-01T00:00:00Z